First person vaccinated during trial of new Ebola jab
· Medical Xpressedited by Andrew Zinin
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process
Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
reputable news agency
proofread
The GIST Add as preferred source
A volunteer was injected Friday with the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola driving a deadly outbreak in the Democratic Republic of Congo, Oxford University said.
More than 1,000 people have been killed in the DRC and Uganda since the outbreak emerged in May, according to the World Health Organization.
Researchers and health organizations have since been racing to get a vaccine or treatment for the relatively rare strain to the clinical trial stage, when it is tested on humans.
Earlier this month, a team at Oxford University in the UK announced it was launching the first trial of its ChAdOx1 BDBV vaccine, which uses the same technology as AstraZeneca's COVID-19 vaccine.
The first dose was administered to a 37-year-old volunteer named Ed Hunt in Oxford on Friday, a university spokesman told AFP.
"We've taken this vaccine candidate from concept to clinic in just eight weeks," David Pulido-Gomez of Oxford's Pandemic Sciences Institute said in a statement.
"Reaching this milestone in such a short timeframe reflects an extraordinary collaborative effort," he added.
The trial received funding from the Coalition for Epidemic Preparedness Innovations (CEPI), while the Serum Institute of India has already manufactured a stockpile of 620,000 doses.
The phase 1 trial plans to assess the safety and effectiveness of the vaccine in 50 healthy adults in the coming weeks. The researchers are currently recruiting more volunteers.
Pending regulatory approval, the team is preparing for more clinical studies of the vaccine with partners in Uganda, Oxford said.
Several other Bundibugyo vaccine candidates are also being urgently developed toward the trial stage, while two potential treatments are being worked on.
The Ebola outbreak is the 17th in the DRC's history, but just the third caused by the Bundibugyo strain, for which there are no approved vaccines or treatments.
WHO chief Tedros Adhanom Ghebreyesus warned last week that the outbreak had, over the past month, "expanded faster than any previous outbreak" of Ebola.
The outbreak has remained concentrated in the vast country's mineral-rich and conflict-plagued northeastern province.
Cases of Ebola, which spreads through close contact and infected bodily fluids, have also been found in four other DRC provinces.
Key medical concepts
Clinical Trials, Phase I as Topic
Clinical categories
Infectious diseasesCommon illnesses & PreventionClinical pharmacology Who's behind this story?
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
© 2026 AFP
Citation: First person vaccinated during trial of new Ebola jab (2026, July 24) retrieved 25 July 2026 from https://medicalxpress.com/news/2026-07-person-vaccinated-trial-ebola-jab.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.